Hypertension

Hypertension-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).

Image View Download All PDFs List View Archive

loading
Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
Aveo Pharmaceuticals, Inc.
May 18, 2017 - N°20170137506

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use ...
Process for the preparation of kinase inhibitors and intermediates thereof
Aerie Pharmaceuticals, Inc.
May 18, 2017 - N°20170137384

Described are processes for the synthesis of certain compounds, useful for treating diseases, e. G. Eye disease, such as glaucoma and ocular hypertension, in a subject.
Method for treating a pulmonary hypertension condition
Gilead Sciences, Inc.
May 18, 2017 - N°20170136016

A method for treating a pulmonary hypertension condition such as pulmonary arterial hypertension (pah) in a subject comprises administering to the subject a therapeutically effective amount of ambrisentan, wherein, at baseline, time from first diagnosis of the condition in the subject is not greater than about 2 years
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Devices and methods for control of blood pressure
Vascular Dynamics, Inc.
May 18, 2017 - N°20170135829

Apparatus and methods are described, including identifying a subject as suffering from hypertension. In response to the identifying (a) a radius of curvature of a first set of at least three regions of an arterial wall of the subject is increased at a given longitudinal location, while (b) allowing the first set of regions of the arterial wall to pulsate. ...
Methods of detecting and treating pulmonary hypertension
Rensselaer Center For Translational Research, Inc.
May 11, 2017 - N°20170131289

The present disclosure describes a method of quantifying amounts of phosphopeptides using isotopically-enriched peptides as internal standards. A kit comprising at least one isotopically-enriched phosphorylated peptide can be used to quantify changes in amounts of phosphopeptides using parallel reaction monitoring mass spectrometry techniques. The invention can be used to indicate the pathologic mechanism, severity of the disease, and treatment response ...
Method for treating secondary pulmonary hypertension
Sonivie Ltd.
May 11, 2017 - N°20170128751

Method for ameliorating secondary pulmonary hypertension in a patient including determining a pulmonary vascular resistance (pvr) of the patient suffering from secondary pulmonary hypertension; assessing a change in the pvr in response to a selection treatment; and treating the patient with a pulmonary artery manipulation device to provide pulmonary artery denervation if the patient is determined to suffer from fixed ...
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 27, 2017 - N°20170112875

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Hypotensive lipid and timolol compositions and methods of using same
Allergan, Inc.
April 27, 2017 - N°20170112853

New compositions for and methods of treating ocular hypertension provide for effective treatment of ocular hypertension often using reduced concentrations of active components. Such compositions include a timolol component and a hypotensive lipid component. The present compositions and methods are relatively straightforward, can be easily produced, for example, using conventional manufacturing techniques, and can be easily and conveniently practiced, for ...
Methods and materials for treating hypertension
Mayo Foundation For Medical Education And Research
April 27, 2017 - N°20170112564

This document provides methods and materials involved in treating hypertension (e. G., age-associated hypertension, resistant hypertension, or chronic refractory hypertension). For example, methods and materials involved in administering one or more sympatholytic agents to a patient to identify the patient as having an elevated baseline level of sympathetic nerve activity and performing renal denervation on the identified patient to reduce ...
Methods, systems and devices for treating hypertension
Rox Medical, Inc.
April 20, 2017 - N°20170106133

Provided is a method of treating arterial hypertension in a patient. The method comprises selecting a patient suffering from arterial hypertension and creating a flow pathway between a first vascular location and a second vascular location. The first vascular location comprises a source of arterial blood and the second vascular location comprises a source of venous blood. The method causes ...
Magnesium compositions and uses thereof for neurological disorders
Neurocentria, Inc.
April 20, 2017 - N°20170106016

A composition for administration to a subject, such as oral administration to a subject, for example, has been provided. Such a composition may comprise at least one magnesium-counter ion compound. A magnesium-counter ion composition described herein may be useful for any of a variety of applications provided herein, such as maintaining, enhancing, and/or improving health, nutrition, and/or another ...
Substituted prolines / piperidines as orexin receptor antagonists
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170101410

The present invention is directed to compounds that modulate the bioactivity of an orexin receptor such as ox1 or ox2, or both; to pharmaceutical compositions and combinations comprising a compound of the invention; to methods of treatment of malconditions in patients wherein modulation of an orexin receptor is medically indicated; and to methods of preparation of compounds of the invention. ...
Urea compounds and their use as enzyme inhibitors
Eolas Therapeutics, Inc.
April 13, 2017 - N°20170101381

Or a pharmaceutically acceptable salt or derivative thereof. The compound may be used in the treatment or prevention of a disorder selected from appetite regulation, obesity, metabolic disorders, cachexia, anorexia, pain, inflammation, neurotoxicity, neurotrauma, stroke, multiple sclerosis, spinal cord injury, parkinson's disease, levodopa-induced dyskinesia, huntington's disease, gilles de la tourette's syndrome, tardive dyskinesia, dystonia, amyotrophic lateral sclerosis, alzheimer's disease, epilepsy, ...
Hypertension Patent Pack
Download 166+ patent application PDFs
Hypertension Patent Applications
Download 166+ Hypertension-related PDFs
For professional research & prior art discovery
inventor
  • 166+ full patent PDF documents of Hypertension-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Salt-free miso production method, salt-free miso, hepatic function improvement agent, and hypertension improvement agent
Masuyamiso Co., Ltd.
April 13, 2017 - N°20170100444

Provided are: a production method for salt-free miso, in which steamed soy beans and koji are pressurized, heated, and fermented; salt-free miso obtained by said production method; and a hepatic function improvement agent and a hypertension improvement agent that contain said salt-free miso as an effective component thereof.
Prevention, treatment and reversal of disease using therapeutically effective amounts of activated fatty acids
Complexa, Inc.
April 06, 2017 - N°20170095437

Various embodiments of this invention are directed to pharmaceutical compositions and methods for treating diseases, including focal segmental glomerulosclerosis or pulmonary arterial hypertension. The compositions of such embodiments include activated fatty acids such as alkyl substituted fatty acids, keto fatty acids and nitro fatty acids. The methods of various embodiments include administering an effective amount of 10-nitro-9(e)-octadec-9-enoic ...
Method of testing for pulmonary hypertension
Tohoku University
March 30, 2017 - N°20170089924

A primary object of the present invention is to provide a method for conveniently and accurately testing for pulmonary hypertension. To achieve this object, the present invention provides a method for testing for pulmonary hypertension using as an indicator the concentration of selenoprotein p protein in a sample derived from a subject.
Pulmonary hypertension biomarker
Novartis Ag
March 30, 2017 - N°20170088897

Pulmonary hypertension is a progressive disease of various origins that is associated with vascular remodelling and results in right heart dysfunction. Accumulating evidence indicates important roles of immune cells and inflammatory chemokines in the pathogenesis and progression of pulmonary hypertension. We have identified ccl21 as anti-remodelling efficacy biomarker for pulmonary hypertension. Ccl21 was found to be highly sensitive and specific ...
Carboxamide inhibitors
Novartis Ag
March 30, 2017 - N°20170088546

The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.
Carboxamide inhibitors
Novartis Ag
March 30, 2017 - N°20170088545

The compounds of formula i demonstrate properties as smurf-1 inhibitors and are thus useful in the treatment of a range of disorders, particularly pulmonary arterial hypertension.
Composition for treating or preventing metabolic disease, containing, as active ingredient, extracellular vesicles derived from ...
Md Healthcare Inc.
March 30, 2017 - N°20170087195

The present invention relates to a pharmaceutical and food composition for treating, preventing, or alleviating a metabolic disease, containing, as an active ingredient, extracellular vesicles derived from akkermansia muciniphila. The composition of the present invention can be used as a pharmaceutical/food composition and the like for treating, preventing, or alleviating metabolic diseases, in particular metabolic diseases such as obesity, ...
Solid forms of an alpha, omega di-substituted dihydroxy cyclopentyl compound and methods for the preparation ...
Allergan, Inc.
March 30, 2017 - N°20170087163

Provided herein are multiple solid forms of a defined α,{acute over (ω)}-disubstituted dihydroxy cyclopentyl compound, and methods for the preparation and use thereof. In one aspect, there are provided crystalline forms of said cyclopentyl compound, and methods for the preparation and use thereof. In another aspect, there are provided substantially amorphous forms of said dihydroxy cyclopentyl ...